Literature DB >> 24937799

Posterolateral lumbar fusion using Escherichia coli-derived rhBMP-2/hydroxyapatite in the mini pig.

Chang-Bae Kong1, Jae Hyup Lee2, Hae-Ri Baek3, Choon-Ki Lee4, Bong-Soon Chang4.   

Abstract

BACKGROUND CONTEXT: Hydroxyapatite (HA) is used as a bone graft extender for posterolateral spinal fusion in human. It is also useful as a recombinant human bone morphogenetic protein (rhBMP)-2 carrier because of its high affinity for rhBMP-2.
PURPOSE: To assess the osteoinductivity of Escherichia coli-derived rhBMP-2 (E-BMP-2) using HA granules as a carrier and to evaluate the bone-forming ability depending on the different dosages of E-BMP-2. STUDY
DESIGN: A mini-pig lumbar posterolateral fusion model using microcomputed tomography (μCT) scanning. PATIENT SAMPLE: Thirty-one adult male mini pigs were randomized into a single control group (n=8) without E-BMP-2 and two experimental groups with two different doses of E-BMP-2 (1 mg per side, n=8 and 3 mg per side, n=15). OUTCOME MEASURES: Outcome was measured by plain radiography, manual palpation, CT, three-dimensional μCT, and histologic examinations.
METHODS: Bilateral intertransverse process arthrodesis was performed, and E-BMP-2 (0, 1.0, 3.0 mg per side) was implanted into the intertransverse space using HA granules as a carrier.
RESULTS: Three mini pigs were removed because of death. Among 28 experimental subjects, 19 animals achieved solid bony union. The fusion rates were 37.5% for control group, 71.4% for 1 mg group, and 84.6% for 3 mg group. Fusion rates were significantly different among groups (p=.031). However, there was no statistically significant difference in fusion rates between 1 and 3 mg groups (p=.587). Thirty-eight intertransverse fusion masses of 19 subjects underwent μCT scanning. The bone volumes determined by μCT were 12,603±3,240 mm(3) for control group, 18,718±3,000 mm(3) for 1 mg group, and 26,768±7,256 mm(3) for 3 mg group, and the difference between groups was statistically significant (p<.001).
CONCLUSIONS: This study shows that E-BMP-2 has osteoinductive activity in dose-dependent fashion, and porous HA granule is suitable for E-BMP-2 carrier in a porcine posterolateral fusion model. These preliminary findings suggest that E-BMP-2-adsorbed porous HA granules could be a novel effective bone graft substitute.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Escherichia coli–derived rhBMP-2; Hydroxyapatite; Mini pig; Osteoinductivity; Posterolateral fusion

Mesh:

Substances:

Year:  2014        PMID: 24937799     DOI: 10.1016/j.spinee.2014.06.007

Source DB:  PubMed          Journal:  Spine J        ISSN: 1529-9430            Impact factor:   4.166


  4 in total

1.  An effective delivery vehicle of demineralized bone matrix incorporated with engineered collagen-binding human bone morphogenetic protein-2 to accelerate spinal fusion at low dose.

Authors:  Weiguo Zhu; Yong Qiu; Fei Sheng; Xinxin Yuan; Leilei Xu; Hongda Bao; Jianwu Dai; Zezhang Zhu
Journal:  J Mater Sci Mater Med       Date:  2017-12-01       Impact factor: 3.896

2.  Engineered collagen-binding bone morphogenetic protein-2 incorporated with platelet-rich plasma accelerates lumbar fusion in aged rats with osteopenia.

Authors:  Weiguo Zhu; Chao Kong; Fumin Pan; Miao Ouyang; Kang Sun; Shibao Lu
Journal:  Exp Biol Med (Maywood)       Date:  2021-03-23

3.  Evaluation of the efficacy and safety of Escherichia coli-derived recombinant human bone morphogenetic protein-2 in transforaminal lumbar interbody fusion to treat degenerative spinal disease: a protocol of prospective, randomized controlled, assessor-blinded, open-label, multicenter trial.

Authors:  Jun-Young Choi; Hyun-Jin Park; Sang-Min Park; Chang-Nam Kang; Kwang-Sup Song
Journal:  J Orthop Surg Res       Date:  2022-08-31       Impact factor: 2.677

4.  Interbody fusion in degenerative lumbar spinal stenosis with additional posterolateral fusion using Escherichia coli-derived bone morphogenetic protein-2: A Pilot study.

Authors:  Sung Hoon Choi; Ja Wook Koo; DaeHyun Choe; Jeong Min Hur; Dong-Hong Kim; Chang-Nam Kang
Journal:  Medicine (Baltimore)       Date:  2020-06-12       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.